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Abstract Background: [11C]Pittsburgh compound B ([11C]PIB) and [18F]-2-fluoro-2-deoxy-D-glucose ([18F]
FDG) PET measure fibrillar amyloid-b load and glucose metabolism, respectively. We evaluated the
impact of these tracers on the diagnostic process in a memory clinic population.
Methods: One hundred fifty-four patients underwent paired dynamic [11C]PIB and static [18F]FDG
PET scans shortly after completing a standard dementia screening. Two-year clinical follow-up data
were available for 39 patients. Parametric PET images were assessed visually and results were re-
ported to the neurologists responsible for the initial diagnosis. Outcome measures were (change
in) clinical diagnosis and confidence in that diagnosis before and after disclosing PET results.
Results: [11C]PIB scans were positive in 40 of 66 (61%) patients with a clinical diagnosis of Alz-
heimer’s disease (AD), 5 of 18 (28%) patients with frontotemporal dementia (FTD), 4 of 5 (80%)
patients with Lewy body dementia, and 3 of 10 (30%) patients with other dementias. [18F]FDG up-
take patterns matched the clinical diagnosis in 38 of 66 (58%) of AD patients, and in 6 of 18 (33%)
FTD patients. PET results led to a change in diagnosis in 35 (23%) patients. This only occurred when
prior diagnostic certainty was ,90%. Diagnostic confidence increased from 71 6 17% before to 87
6 16% after PET (p , .001). Two-year clinical follow-up (n 5 39) showed that [11C]PIB and [18F]
FDG predicted progression to AD for patients with mild cognitive impairment, and that the diagnosis
of dementia established after PET remained unchanged in 96% of patients.
Conclusions: In a memory clinic setting, combined [11C]PIB and [18F]FDG PET are of additional
value on top of the standard diagnostic work-up, especially when prior diagnostic confidence is low.
 2013 The Alzheimer’s Association. All rights reserved.
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1. Introduction
The diagnosis of patients with cognitive and/or behav-
ioral symptoms can be complicated as different types of
neurodegenerative disorders show overlap in clinical pre-
sentation, particularly in patients with an early onset of
disease (,65 years) [1]. Furthermore, it is difficult to
identify patients in a prodromal stage of Alzheimer’s dis-
ease (AD) or other forms of dementia based on clinical
symptoms alone. Improvement of early and differential
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diagnosis is desirable, especially in view of emerging
disease-modifying agents. Over the past decades, several
biomarkers have been developed to increase diagnostic
accuracy in neurodegenerative diseases. These biomarkers
have caused a major paradigm shift and have been incor-
porated in recently revised criteria that aim for more
accurate and earlier diagnosis of AD, frontotemporal de-
mentia (FTD), and dementia with Lewy bodies (DLB)
[2–6].
Molecular imaging biomarkers most frequently used in
the diagnosis of dementia are [18F]-2-fluoro-2-deoxy-D-glu-
cose ([18F]FDG) and [11C]Pittsburgh compound B ([11C]
PIB), which can be imaged using positron emission tomog-
raphy (PET). [18F]FDG is the more established tracer and
provides a measure of metabolic activity of the brain. [18F]
FDG does not directly measure pathology, but rather the ex-
tent of metabolic impairment predicts cognitive decline, and
is closely related to disease severity [7–9]. Mapping the
pattern of glucose hypometabolism has high sensitivity
(94%) for diagnosing AD, but specificity is lower (73%),
as other neurodegenerative diseases can induce a decrease
in glucose metabolism resembling the pattern seen in AD
[10–12]. Reading [18F]FDG images requires a well-trained
eye, and even then only moderate interrater reliability is ac-
complished [13,14].
More recently, [11C]PIB [15] became available for
in vivo detection of fibrillary amyloid plaques, a neuropath-
ologic hallmark of AD. Probing the underlying neuropath-
ologic substrate may be helpful in identifying the correct
type of dementia, particularly in patients with an atypical
presentation [16]. [11C]PIB discriminates AD patients
from cognitively normal elderly [15,17,18], is a strong
predictor of progression of mild cognitive impairment
(MCI) to AD [19–21], and distinguishes AD reasonably
well from other forms of dementia such as FTD [16,22]
and vascular dementia (VaD) [23]. Patients with DLB,
however, show positive [11C]PIB scans in up to 89% of
cases [24], which corresponds to increased amyloid burden
found at postmortem examination in the majority of DLB
patients [25]. Visual assessment of parametric [11C]PIB
images is straightforward and shows a high level of agree-
ment between readers [14].
The current literature on [18F]FDG and especially [11C]
PIB PET typically consists of comparisons of highly se-
lected diagnostic groups. In general, these studies show
good correspondence between clinical diagnosis and neuro-
imaging results. The potential lack of variation in pretest
diagnostic certainty, however, may overestimate this con-
cordance and may actually be lower in a more representa-
tive sample of a memory clinic population. The aim of
the present study was therefore to assess the impact of
[11C]PIB and [18F]FDG PET on the diagnostic process in
a large sample of patients from a memory clinic, encom-
passing a wide spectrum of cognitive and/or behavioral
symptoms.
2. Methods
2.1. Subjects and diagnostic procedure
Between March 2009 and September 2011, 154 patients
were included from the outpatient memory clinic of the
VU University Medical Center. All patients underwent
standard diagnostic work-up for dementia consisting of
medical history, informant based history, physical and neu-
rologic examinations, screening laboratory tests, brain
magnetic resonance imaging (MRI), and neuropsychologic
testing [26]. This was followed by paired [11C]PIB
and [18F]FDG PET scans. To ensure substantial variation
in pretest diagnostic certainty, patients were recruited
from two cohorts. One hundred nine patients were
enrolled in the Center for Translational Molecular Medi-
cine (CTMM) Leiden Alzheimer Research Netherlands
(LeARN) project. The aim of this project is to evaluate
the cost-effectiveness of ancillary investigations in
a memory clinic setting, encompassing a wide spectrum
of cognitive and/or behavioral symptoms. Patients with
a Mini-Mental State Examination (MMSE) score of 20
and a maximum clinical dementia rating (CDR) of 1, with-
out major neurologic and psychiatric disorders, recent vas-
cular events, and excessive substance abuse, could
participate in LeARN. In a second group of 45 patients,
[11C]PIB and [18F]FDG PET scans were performed in
case of substantial uncertainty about the diagnosis after
the standard diagnostic work-up. The aforementioned in-
clusion criteria did not apply to the latter group of patients.
A clinical diagnosis was made by consensus of a multidisci-
plinary team using established clinical criteria [27–31].
Diagnostic categories were AD, FTD, VaD, DLB,
dementia-other (i.e., corticobasal degeneration [CBD]
and progressive supranuclear palsy [PSP]), MCI, subjective
memory complaints (SMC), psychiatry, and neurology-
other (i.e., normal pressure hydrocephalus). In December
2011, 2-year clinical follow-up data (consisting of neuro-
logic and neuropsychologic reevaluation, without neuroi-
maging) were available for 39 patients. All patients gave
written informed consent after they had received a complete
written and verbal description of the study. The medical
ethics review committee of the VU University Medical
Center approved the study.
2.2. PET imaging and analysis
PET procedures have been reported elsewhere [26].
Briefly, PET scanning was performed on an ECAT
Exact HR1 scanner (Siemens/CTI, Knoxville, TN). After
a 10-minute transmission scan, a dynamic 90-minute emis-
sion scan was started simultaneously with an intravenous in-
jection of 367 6 43 MBq [11C]PIB. After coregistration of
the MRIs to the corresponding PET images, the data were
further analyzed using PVELab [32]. Regions of interest
(ROIs) were projected onto nondisplaceable binding
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potential (BPND) images of [
11C]PIB. These images were
generated by applying a two-step basis-function implemen-
tation of the simplified reference tissue model (RPM2) [33].
For 12 patients, standardized uptake value ratio (SUVr) im-
ages of [11C]PIB for the interval between 60 and 90 minutes
[34], rather than BPND images, were generated because of
patient movement and/or technical issues. Cerebellar gray
matter was chosen as reference tissue.
After an interval of at least 2 hours to allow for decay of
[11C]PIB, an intravenous bolus of approximately 185 MBq
of [18F]FDG was administered. All subjects rested for 15
minutes before and for 35 minutes after injection with
eyes closed and ears unplugged in a dimly lit room with
minimal background noise. Next, patients underwent
a 10-minute transmission scan followed by a 15-minute
emission scan. Parametric SUVr images were extracted
from the interval between 45 and 60 minutes after injection.
In addition, [18F]FDG scans were analyzed using the
PMOD Alzheimer’s discrimination (PALZ) tool [35].
Briefly, the PALZ tool compares age-corrected [18F]FDG
uptake with predicted uptake. The t values of all abnormal
voxels within a predefined AD mask are summed, yielding
an AD t-sum that automatically classifies the scan into ei-
ther normal or abnormal.
For both tracers, T1-weighted MRI (3T Signa HDxt;
General Electric, Milwaukee, WI) scans were used for core-
gistration and segmentation. Due to tracer synthesis failure,
21 patients did not undergo [11C]PIB and [18F]FDG PET
scans on the same day but within an interval of, at most, 4
weeks. [11C]PIB and [18F]FDG PET scans were performed
2 6 1 months after dementia screening.
2.3. Visual assessment of parametric [11C]PIB and [18F]
FDG images
BPND (n 5 142) and SUVr (n 5 12) images of [
11C]PIB
and SUVr images of [18F]FDG were assessed visually by an
experienced nuclear medicine physician (B.v.B.). [11C]PIB
PET scans were rated as either PIB-positive (PIB1; binding
in more than one cortical brain region; i.e., frontal, parietal,
temporal, or occipital) or PIB-negative (PIB2, predominantly
white matter binding). For [18F]FDG PET scans, the reader
had access to both the original images and the results of the
PALZ tool. The nuclear medicine physicianmade the final de-
cision. [18F]FDG PET scans were interpreted as either normal
or deviant and suggestive for AD (posterior cingulate and pa-
rietotemporal hypometabolism), FTD (frontotemporal meta-
bolic impairment), DLB (occipital hypometabolism with
relatively intact posterior cingulate gyrus), or dementia-
other (PSP: mesenchepalon, prefrontal, caudate nucleus,
and thalamus hypometabolism; CBD: asymmetric hypome-
tabolism with involvement of the basal ganglia). [11C]PIB
and [18F]FDG scans were assessed together and the reader
had access to the clinical differential diagnosis.
2.4. Assessment of impact PET on diagnostic process
After clinical assessment, that is, prior to PET, one of
the neurologists (either N.D.P., A.W.L., Y.A.L.P., or P.S.)
indicated the most probable (consensus) diagnosis on
a questionnaire (refer to form in supplementary material).
It was mandatory for the neurologists to select a diagnosis.
In addition, the level of diagnostic certainty was estimated
on a scale ranging from 0% to 100%. Next, PET scanning
and subsequent rating was performed and the scans were
discussed at a monthly meeting in the presence of the neu-
rologists. Subsequently, the most probable diagnosis and
corresponding diagnostic certainty were indicated again
by the neurologist responsible for the initial diagnosis,
now taking into account the findings on PET in addition
to the clinical information. Furthermore, it was indicated
whether both tracers, [11C]PIB alone, [18F]FDG alone, or
none, contributed to the diagnostic process. To specify
the utility of the individual tracers, the neurologists were
asked whether [11C]PIB and [18F]FDG improved, con-
fused, or had only little or no effect on their understanding
of a patient’s disease.
2.5. Statistics
Differences in baseline values between groups were as-
sessed using analysis of variance (ANOVA), Kruskal–Wallis
tests, and c2 tests, where appropriate. Paired-samples t tests
were used to assess change of diagnostic certainty after PET.
Independent-sample t tests were used to assess differences in
diagnostic certainty prior to PET between AD patients with
PIB1 and PIB2 PET scans, and between patients with and
without diagnostic alteration after PET.
3. Results
3.1. Subjects
After the initial standard dementia work-up, patients re-
ceived the following clinical diagnoses: AD (n 5 66);
MCI (n 5 30); SMC (n 5 15); FTD (n 5 18); DLB (n 5
5); dementia-other (n 5 10); psychiatry (n 5 6); and
neurology-other (n 5 4). Characteristics according to diag-
nostic group are presented in Table 1. Diagnostic certainty
did not differ between groups prior to PET.
3.2. Visual PET ratings
Table 1 also provides visual ratings of [11C]PIB and
[18F]FDG PET scans. Most AD patients had PIB1 scans
(61%) and most patients with non-Alzheimer’s dementia
had [11C]PIB2 scans (67%). Consequently, still relatively
high numbers of PIB2 scans were seen in patients with
a clinical AD diagnosis (39%), and PIB1 scans in pa-
tients with a clinical diagnosis of FTD (28%), DLB
(80%), “dementia-other” (30%), MCI (57%), and SMC
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(20%). Furthermore, [18F]FDG uptake patterns matched
the clinical diagnosis of AD in 58% and of FTD in
33% of cases. [18F]FDG scans were normal in 93% of
SMC patients.
3.3. Change of diagnosis
The clinical diagnosis changed in 35 of the 154 patients
(23%) after disclosing PET results. Figure 1 shows an over-
view of clinical diagnoses and corresponding diagnostic cer-
tainty before and after PET for all dementia patients. In
patients with a clinical diagnosis of AD (n 5 66), the diag-
nosis remained AD in 67% and was changed in 33% into ei-
ther FTD (17%), “dementia-other” (6%), psychiatry (5%),
DLB (3%), neurology-other (2%), or vascular dementia
(2%). Figure 2 shows an illustrative patient whose clinical
diagnosis changed from AD to CBD after revelation of
a [11C]PIB2 scan and a [18F]FDG pattern suggestive of
CBD. A clinical diagnosis of FTD (n 5 18) remained FTD
in 61% of cases, with the remaining 39% changing into
AD (22%), SMC (6%), DLB (6%), or psychiatry (6%) after
PET. The diagnosis of patients in the “dementia-other”
category (n 5 10) changed to AD in 2 patients (20%), and
a clinical diagnosis of DLB (n 5 5) was changed to AD in
1 case (20%) after PET. Two patients initially diagnosed
as psychiatric or “neurology-other” were classified as FTD
patients after PET. All clinical diagnoses of SMC or MCI,
by definition, remained unchanged after PET.
3.4. Diagnostic certainty
For all patients together, diagnostic certainty increased
from 71 6 17% before PET to 87 6 16% after PET
(p , .001). Diagnostic confidence prior to PET was lower
for diagnoses that changed after PET (626 18%) compared
with those that remained unchanged (73 6 15%, p , .05).
Also, diagnostic confidence prior to PET was higher in pa-
tients with a clinical AD diagnosis who showed PIB1 PET
scans (75 6 16%) compared with those who showed PIB2
scans (64 6 20%, p , .05). A change in clinical diagnosis
only occurred when diagnostic confidence prior to PET
was ,90% (Figure 1). Percent change in diagnosis after
PET increased with lower pre-PET diagnostic confidence
of the clinician (Figure 3).
3.5. Contribution of [11C]PIB and [18F]FDG to
diagnostic process
In patients whose diagnosis changed after PET, 7 were
PIB1 and 28 were PIB2. Corresponding patterns of [18F]
FDG uptake fitted best to AD (12 cases), FTD (9 cases),
DLB (2 cases), and dementia-other (2 cases), or were consid-
ered normal (10 cases). As shown in Table 2, combined [11C]
PIB and [18F]FDG contributed most often to the diagnosis
(104 cases), followed by [11C]PIB only (29 cases) and
[18F]FDG only (11 cases).
3.6. Utility of [11C]PIB and [18F]FDG
[11C]PIB provided information that improved the clini-
cians understanding of a patient’s disease in 125 (81%) pa-
tients, whereas, for [18F]FDG, this was the case in 98
(64%) patients (refer to supplementary figure). [11C]PIB
and [18F]FDG each confused the clinician in 8 (6%)
and 12 (10%) cases, respectively. [18F]FDG more often
(43 cases, 34%) had only little or no effect on the clini-
cian’s comprehension of a patient’s disease than [11C]PIB
(20 cases, 16%).
Table 1
Demographic and clinical characteristics according to clinical diagnosis prior to PET
AD
(n 5 66)
MCI
(n 5 30)
SMC
(n 5 15)
FTD
(n 5 18)
DEM-other
(n 5 10)
DLB
(n 5 5)
Psychiatry
(n 5 6)
NEU-other
(n 5 4)
Age 64 6 7 64 6 9 64 6 6 67 6 6 65 6 10 65 6 7 56 6 7 59 6 9
Gender (M/F) 44/22 23/7* 7/8 12/6 5/5 3/2 4/2 2/2
MMSE 21 6 5y 27 6 2 28 6 2 23 6 5z 25 6 3 22 6 2 26 6 4 26 6 4
CDR 0.9 6 0.4x 0.560.1 0.4 6 0.3 0.8 6 0.7 1.2 6 0.7 1.0 6 0 0.3 6 0.3 0.9 6 0.3
% Pre-PET diagnostic
certainty
71 6 19 69615 79 6 16 71 6 16 62 6 12 66 6 11 736 13 73 6 10
% [11C]PIB1 61 57 20 28 30 80 0 50
[18F]FDG pattern 10 normal,
38 AD,
8 FTD,
2 DLB,
7 Dem-other
15 normal,
14 AD,
1 DLB,
14 normal,
1 FTD
4 normal,
4 AD
6 FTD
3 DLB
1 Dem-other
1 normal,
3 AD,
2 FTD,
4 Dem-other
4 AD,
1 DLB
4 normal,
1 FTD,
1 Dem-other
2 normal,
2 AD
Data are presented as mean6 SD unless indicated otherwise. Differences between groups were assessed using ANOVAwith post hoc Bonferroni tests (age
and MMSE), c2 tests (gender), and Kruskal–Wallis with post hoc Mann–Whitney U tests (CDR). AD, Alzheimer’s disease; MCI, mild cognitive impairment;
SMC, subjective memory complaints; FTD, frontotemporal dementia; DEM-other, dementia-other; DLB, dementia with Lewy bodies; NEU-other, neurology-
other; M, male; F, female; MMSE, Mini-Mental State Examination; CDR, clinical dementia rating.
*MCI . SMC: p , .05.
yAD , MCI, SMC, and psychiatry: p , 0.05.
zFTD , SMC: p , .05.
xAD . MCI, SMC, and psychiatry: p , .05.
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3.7. Clinical follow-up
Two-year clinical follow-up data were available for 39
patients. Six of 7 patients with MCI and [11C]PIB1 PET
scans progressed to AD during follow-up, of whom 5 had
a baseline [18F]FDG scan suggestive of AD (Table 3).
None of the 5 MCI patients with [11C]PIB2 and normal
[18F]FDG PET scans converted to AD. SMC patients
did not convert during follow-up. Post-PET diagnosis
changed in only 1 of 23 dementia patients (4%) (refer to
supplementary table).
4. Discussion
In this study we have investigated the added value of
combined [11C]PIB and [18F]FDG PET in the diagnostic
process in a large sample of patients from a specialized
memory clinic. The main result was that molecular imaging
is indeed of additional value over standard diagnostic work-
up, given that 23% of the initial clinical diagnoses changed
and that diagnostic confidence increased after PET. The
lower the diagnostic certainty prior to PET, the larger the
percent change in diagnosis after PET. Two-year clinical
follow-up in a small subset of patients (n 5 39) showed
that PET predicted progression to AD in MCI patients and
that the clinical dementia diagnoses established after PET re-
mained unchanged in 96% of cases. Application of [11C]PIB
and [18F]FDG PET seems therefore most useful when confi-
dence in a dementia diagnosis is low, and to increase prog-
nostic certainty in patients with MCI.
There was a frequent mismatch between clinical diagno-
sis and PET findings in this study. Absence of [11C]PIB
binding in clinically diagnosed AD patients is a common
finding, but in general this is less than the 39% observed
in the present study [15]. False negative findings cannot
be ruled out, as [11C]PIB PET may not be able to detect
more soluble species of Ab-42 or atypical amyloid deposits
[36]. This is rare, however, and it is more likely that these
patients present with an AD-like phenotype that originates
from non-amyloidogenic neuropathology. On the other
hand, [11C]PIB-positive scans are regularly observed in pa-
tients with non-AD dementias, particularly in FTD and in
DLB [16,22,24]. Autopsy studies in DLB patients have
proven that these are not false positive findings but truly
reflect AD pathology, next to the presence of Lewy bodies
[25]. With respect to FTD, it is known from postmortem
studies that about 15%–20% of clinical FTD patients actu-
ally have AD [37]. These patients potentially mimic an
FTD clinical syndrome that is actually driven by AD pathol-
ogy, also known as “the frontal variant of AD” [38]. Alter-
natively, comorbid FTD and AD pathology may be present,
with FTD pathology as the force driving the clinical presen-
tation and amyloid pathology as a byproduct of aging. In the
present study, clinicians tended to use [11C]PIB PET mostly
Fig. 1. Scatterplot shows diagnosis data before and after PET for all dementia patients (n5 99). Patients in the upper right quadrant were diagnosed with AD at
both baseline and after disclosure of PET results. Patients in the lower left quadrant were consistently diagnosed with a non-AD type of dementia. Patients in the
left upper quadrant had a clinical diagnosis of a non-AD type of dementia prior to PET, but their diagnoses changed to AD after PET. In the right lower quadrant,
clinically diagnosed AD patients are presented, whose diagnoses were changed after PET. The legend specifies the direction of diagnostic changes. The X- and
Y-axes represent the confidence levels of the clinicians in the diagnosis before and after PET, respectively. AD, Alzheimer’s disease; FTD, frontotemporal de-
mentia; DLB, dementia with Lewy bodies; VaD, vascular dementia; SMC, subjective memory complaints.
R. Ossenkoppele et al. / Alzheimer’s & Dementia 9 (2013) 414–421418
to rule out AD, which seems justified according to the afore-
mentioned neuropathologic findings.
Unlike [11C]PIB, [18F]FDG does not provide dichoto-
mous information, as metabolic impairment occurs in
many brain disorders that cause cognitive deterioration
[10]. [18F]FDG PET, however, can be used to identify
patterns of cerebral glucose hypometabolism that character-
ize several neurodegenerative diseases. Due to its close rela-
tion with neuronal function, and therefore cognitive status,
[18F]FDG PET can be helpful in diagnostic dilemmas [10].
In the present study, discrepancies between clinical diagno-
sis and [18F]FDG PET findings were common. This may be
explained by diagnostic misclassification or by patients with
atypical clinical presentations and equivalent patterns of glu-
cose hypometabolism or by patients with an typical clinical
presentation but atypical [18F]FDG uptake.
The case presented in Figure 2 illustrates the synergistic
effect of using both pathophysiologic and metabolic tracers.
Indeed, clinicians indicated that the combination of [11C]PIB
and [18F]FDG most often contributed to the diagnosis, fol-
lowed by [11C]PIB alone and [18F]FDG alone. Cases in
which [11C]PIB was decisive were mainly initial clinical di-
agnoses of SMC,MCI, or AD, whereas [18F]FDGwas essen-
tial in some cases with a clinical diagnosis of FTD, DLB, or
psychiatry. Based on the present study, combining [11C]PIB
and [18F]FDGPET seemsmost useful in patientswith low di-
agnostic certainty after standard diagnostic work-up. Cost-
effectiveness of both [11C]PIB and [18F]FDG in a memory
clinic setting have yet to be proven, but, assuming that PET
improves diagnostic accuracy, this will be greatly enhanced
by the availability of disease-modifying agents in the future.
Fig. 2. Example of a 59-year-old man who visited the memory clinic for
a second opinion. He presented with memory problems and spatial disorien-
tation. This was confirmed by his spousewho also mentioned several behav-
ioral problems, including aggression and apathy. Neuropsychologic testing
revealed visuospatial disturbances, memory deficits, and low MMSE (22)
and CAMCOG (80) scores. Frontotemporoparietal brain atrophy was ob-
served on MRI, most pronounced in the right hemisphere. Differential diag-
nosis after the multidisciplinary consensus meeting consisted of: (1)
atypical Alzheimer’s disease (AD); (2) corticobasal degeneration (CBD);
or (3) behavioral variant frontotemporal dementia. For this study, the prob-
ability diagnosis was set to ADwith a diagnostic certainty of 50%. [11C]PIB
PET showed predominantly white matter binding and the diagnosis of AD is
therefore highly unlikely. [18F]FDG PET displayed extremely asymmetric
metabolic impairment in the right hemisphere with involvement of the basal
ganglia. This pattern is suggestive for CBD. According to these PET find-
ings, the clinician changed the diagnosis to CBD with a diagnostic certainty
of 90%. Two-year follow-up revealed cognitive deterioration (MMSE de-
clined to 12), further progression of brain atrophy and a disease course
that fits the diagnosis of CBD.
Fig. 3. Bar diagrams indicating the percentage of diagnoses that changed af-
ter disclosing PET results as a function of diagnostic certainty prior to PET.
Abbreviations: AD, Alzheimer’s disease; FTD, frontotemporal dementia.
Table 2
Contribution of [11C]PIB and [18F]FDG to diagnosis
Diagnosis
prior to PET
[11C]PIB1
[18F]FDG
[11C]PIB
only
[18F]FDG
only
None
of both
Whole group 104/68% 29/28% 11/7% 10/6%
AD 45/68% 15/23% 3/5% 3/5%
MCI 19/63% 8/27% 1/3% 2/7%
SMC 7/47% 5/33% 1/7% 2/13%
FTD 14/78% 0/0% 3/17% 1/6%
Dementia-other 8/80% 0/0% 1/10% 1/10%
DLB 4/80% 0/0% 1/20% 0/0%
Psychiatry 4/67% 1/17% 1/17% 0/0%
Neurology-other 3/75% 0/0% 0/0% 1/25%
Data are presented as number/percent. Neurologists indicated whether
both tracers, [11C]PIB alone, [18F]FDG alone, or none, contributed to the
diagnostic process. AD, Alzheimer’s disease; MCI, mild cognitive impair-
ment; SMC, subjective memory complaints; FTD, frontotemporal demen-
tia; DLB, dementia with Lewy bodies.
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The results of our study cannot simply be generalized to
a general memory clinic population. These patients had vis-
ited a last resort memory clinic, most of them for a second
or third opinion. The relatively young age of the patients
(64 years, on average)make an initial diagnosis more difficult
as clinical presentations tend to overlap between diagnostic
categories and thismaynot be representative for an older sam-
ple [1]. Furthermore, a subset of this sample underwent PET
for diagnostic purposes because standard diagnostic work-up
was not sufficient. All these factors together complicate the
interpretation of the present results. In addition, the study de-
sign may have affected the outcome as it was mandatory for
the neurologists to select a probability diagnosis, even in com-
plex cases that would usually be postponed, when awaiting
clinical follow-up and/or additional investigations. Another
potential limitation of this study is the lack of postmortem
verification, as no autopsy data were available. Alternatively,
a subset of patients underwent 2-year clinical follow-up and,
in these patients, the post-PET diagnoses remained stable in
the dementia patients. Finally, [11C]PIB and [18F]FDG were
always assessed together and the nuclear medicine physician
was provided with the clinical differential diagnosis, which
may have affected the interpretation of both scans.
In conclusion, in a memory clinic, [11C]PIB and [18F]
FDG PET have additional value beyond standard diagnostic
work-up. Molecular imaging in this setting is most useful for
early diagnosis of AD and in cases of high diagnostic uncer-
tainty after standard work-up.
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